Perspective Therapeutics (CATX) EBITDA (2010 - 2026)

Perspective Therapeutics has disclosed EBITDA across 17 years of filings, most recently posting -$29.3 million for Q2 2026.

• In Q2 2026, EBITDA fell 21.71% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$121.8 million (down 11.24% YoY), while the FY2025 annual figure was -$113.6 million, down 24.95% from the prior year.
• EBITDA came in at -$29.3 million for Q2 2026 at Perspective Therapeutics, down from -$28.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.4 million in Q1 2022 to a low of -$45.0 million in Q4 2024.
• Average EBITDA over 5 years is -$17.6 million, with a median of -$13.6 million recorded in 2024.
• Year-over-year, EBITDA slumped 609.38% in 2023 and advanced 14.9% in 2025.
• Over 5 years, EBITDA stood at -$5.6 million in 2022, then slumped by 107.72% to -$11.7 million in 2023, then slumped by 285.27% to -$45.0 million in 2024, then grew by 14.9% to -$38.3 million in 2025, then climbed by 23.57% to -$29.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$29.3 million in Q2 2026, -$28.3 million in Q1 2026, and -$38.3 million in Q4 2025.